Pain control and functional improvement in patients treated by autologous conditioned serum after failure of platelet rich plasma treatments in knee osteoarthritis

被引:4
作者
Leone, Rosa [1 ]
de Rosa, Alessandro [1 ]
Iudicone, Paola [1 ]
Fioravanti, Daniela [1 ]
Capua, Giuseppe [2 ]
Rossetti, Francesca [3 ]
Isgro', Maria Antonietta [1 ]
Pierelli, Luca [1 ,4 ]
机构
[1] San Camillo Forlanini Hosp, Transfus Med, Circonvallaz Gianicolense 87, I-00152 Rome, Italy
[2] San Camillo Forlanini Hosp, Sports Med Unit, Rome, Italy
[3] San Camillo Forlanini Hosp, Orthoped Unit, Rome, Italy
[4] Sapienza Univ, Dept Expt Med, Rome, Italy
关键词
autologous conditioned serum; knee osteoarthritis; pain control; INTERLEUKIN-6; PLACEBO; DISEASE; BURDEN;
D O I
10.1111/tme.12801
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To assess the efficacy of autologous conditioned serum (ACS) for the treatment of patients with knee osteoarthritis after failure of medical treatments and platelet rich plasma (PRP) injections. Background Knee osteoarthritis is the most common form of arthritis. Prior to prosthetic surgery these patients might benefit from medical treatments, physiotherapy, and in case of their ineffectiveness, from autologous blood component injections. Methodology We have treated 30 patients with Kellgren-Lawrence I-III knee osteoarthritis with ACS after failure of standard medical treatments/physiotherapy and platelet rich plasma (PRP) injections for a full cycle, within the previous year from enrollment. Results: ACS administration was performed in all patients with mild side effects and produced prompt (1 month) improvements of VAS and Lequesne scales in 67% of patients and this result persisted at 6 and 12 months. No relationship between the rate of response and Kellgren-Lawrence scale at enrollment was observed whilst responders had a significantly higher amount of interleukin-1 receptor antagonist (IL1-RA) in ACS as compared to nonresponders. Conclusion The present study confirms the efficacy of ACS in pain control and functional recovery of patients with knee osteoarthritis resistant to medical and PRP treatment. These results were obtained in a well-defined cohort of resistant patients and seem to be related with IL1-RA content in injected ACS.
引用
收藏
页码:357 / 364
页数:8
相关论文
共 18 条
[11]   Biomarker of extracellular matrix remodelling C1M and proinflammatory cytokine interleukin 6 are related to synovitis and pain in end-stage knee osteoarthritis patients [J].
Radojcic, Maja R. ;
Thudium, Christian S. ;
Henriksen, Kim ;
Tan, Keith ;
Karlsten, Rolf ;
Dudley, Amanda ;
Chessell, Iain ;
Karsdal, Morten A. ;
Bay-Jensen, Anne-Christine ;
Crema, Michel D. ;
Guermazi, Ali .
PAIN, 2017, 158 (07) :1254-1263
[12]   Osteoarthritis treatment using autologous conditioned serum after placebo Patient considerations and clinical response in a non-randomized case series [J].
Rutgers, Marijn ;
Creemers, Laura B. ;
Yang, Kiem Gie Auw ;
Raijmakers, Natasja J. H. ;
Dhert, Wouter J. A. ;
Saris, Daniel B. F. .
ACTA ORTHOPAEDICA, 2015, 86 (01) :114-118
[13]   Intra-Articular Injections of a Whole Blood Clot Secretome, Autologous Conditioned Serum, Have Superior Clinical and Biochemical Efficacy Over Platelet-Rich Plasma and Induce Rejuvenation-Associated Changes of Joint Metabolism: A Prospective, Controlled Open-Label Clinical Study in Chronic Knee Osteoarthritis [J].
Shirokova, Larisa ;
Noskov, Sergey ;
Gorokhova, Victoria ;
Reinecke, Julio ;
Shirokova, Ksenia .
REJUVENATION RESEARCH, 2020, 23 (05) :401-410
[14]   The Anti-inflammatory and Matrix Restorative Mechanisms of Platelet-Rich Plasma in Osteoarthritis [J].
Sundman, Emily A. ;
Cole, Brian J. ;
Karas, Vasili ;
Della Valle, Craig ;
Tetreault, Mathew W. ;
Mohammed, Hussni O. ;
Fortier, Lisa A. .
AMERICAN JOURNAL OF SPORTS MEDICINE, 2014, 42 (01) :35-41
[15]   Autologous conditioned serum: clinical and functional results using a novel disease modifying agent for the management of knee osteoarthritis [J].
Vitali, Matteo ;
Ometti, Marco ;
Drossinos, Andreas ;
Pironti, Pierluigi ;
Santoleri, Luca ;
Salini, Vincenzo .
JOURNAL OF DRUG ASSESSMENT, 2020, 9 (01) :43-51
[16]  
Vos T, 2013, LANCET, V381, P628
[17]  
Woolf AD, 2003, B WORLD HEALTH ORGAN, V81, P646
[18]   Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial [J].
Yang, K. G. Auw ;
Raijmakers, N. J. H. ;
van Arkel, E. R. A. ;
Caron, J. J. ;
Rijk, P. C. ;
Willems, W. J. ;
Zijl, J. A. C. ;
Verbout, A. J. ;
Dhert, W. J. A. ;
Saris, D. B. F. .
OSTEOARTHRITIS AND CARTILAGE, 2008, 16 (04) :498-505